Mereo BioPharma Group, a UK-based specialty biopharma company, has completed patient enrolment for a phase 2b clinical trial of BPS-804 (Setrusumab) intended for the treatment of osteogenesis imperfect (OI), it was reported yesterday.
The product has received Orphan Drug Designation from both the US Food and Drug Administration (FDA) and the European Medicines Agency for the product for OI, a form of brittle bone disease.
The investigational OI drug has also been accepted into the European Medicines Agency's Adaptive Pathways Program and was offered PRIority MEdicines (PRIME) designation.
The trial is a multi-centre, randomised, double-blind, dose-finding phase 2b study named ASTEROID and will assess the drug in a total of 112 adult patients across the United States and Europe, according to the company.
Fondazione Telethon reports positive opinion for Waskyra marketing authorisation in Europe
Maxx Orthopedics Receives FDA 510(k) Clearance for Its Libertas® Bipolar Hip System
CHMP issues positive opinion for DAWNZERA in hereditary angioedema
Merck to acquire Cidara Therapeutics in USD9.2bn deal to expand antiviral portfolio
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
Ascletis Pharma announces ASC36 and ASC35 co-formulation for clinical development
EirGenix signs second global exclusive licensing deal with Sandoz
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
enGene reports 62% six-month complete response rate for detalimogene in LEGEND trial
Nurami Medical completes Phase 1 milestones in EIC-backed grant for Artifix
Avingtrans subsidiary Adaptix secures FDA clearance for 3D orthopaedic imaging system
Innate Pharma cleared by FDA to launch TELLOMAK 3 Phase 3 trial of lacutamab in CTCL